• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 5 Next >
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 02, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
February 18, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 09, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
January 09, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 10, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 23, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 21, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 15, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
January 12, 2026
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
November 20, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
November 05, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
October 23, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Industry and Investor Conferences in October 2025
October 02, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
September 15, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
September 02, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
August 13, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
August 12, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
August 08, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
August 01, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
July 21, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
July 18, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
July 17, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
June 23, 2025
From Ocugen
Via GlobeNewswire
Tickers CARM OCGN
News headline image
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
June 16, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen To Present at BIO International Convention 2025
June 11, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
June 05, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
May 27, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with First Quarter 2025 Financial Results
May 09, 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap